Dr. Herman Jay H. Herman, M.D.

Contact Dr. Herman

111 S. 11th Street
Suite 8220
Philadelphia, PA 19107

(215) 955-8244
(215) 923-9387 fax

Medical School
M.D., Harvard Medical School, 1977

B.A., Emory University, Humanities, 1973

Board Certification
Board Certification, American Board of Pediatrics, Pediatric Hematology/Oncology, 1987

Board Certification, American Board of Pediatrics, Pediatrics, 1981

Special Qualification, American Board of Pathology, Blood Banking, 1990

University Appointment
Professor
Director, Blood Bank, Transfusion Medicine, Therapeutic Apheresis and Blood Donation Program

Research and Clinical Interests
Dr. Jay H. Herman is the Director of Transfusion Medicine for Thomas Jefferson Hospital, which includes the Blood Bank and Transfusion Service, Therapeutic Apheresis and our own Blood Donor Program. He graduated from Harvard Medical School, and had post-graduate training in Pediatrics, Pediatric Hematology/Oncology, Adult Hematology, Clinical Pathology and Transfusion Medicine/Blood Banking. His interests have focused in the fields of platelet transfusion practice, platelet transfusion refractoriness, platelet and neutrophil serology, antigen characterization and identification, pediatric/neonatal transfusion, immunohematologic complications of stem cell transplantation, new apheresis technology and most recently hypotensive transfusion reactions. Dr. Herman is a nationally prominent expert in Transfusion Medicine and was recruited by the American Association of Blood Banks to develop and edit books on Platelet Transfusion Therapy and Platelet Alloimmunity and Pediatric Transfusion Therapy.

Platelet refractoriness;
Platelet and granulocyte serology;
Neonatal alliommune disorders;
Post-transplantation immune cytopenias;
Platelet transfusion therapy;
Pediatric/neonatal transfusion;
Stem cell collection and processing.

 

Publications

Most recent Peer-reviewed Publications

  1. RhIG for the treatment of immune thrombocytopenia: Consensus and controversy (CME)
  2. In Reply
  3. Prevention of D sensitization after mismatched transfusion of blood components: Toward optimal use of RhIG
  4. Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity
  5. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation
  6. Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation
  7. Acute hypertensive transfusion reactions
  8. Alternative explanation for "muddy plasma" [3]
  9. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: Case report and review of the literature
  10. Apheresis platelet transfusions: Does ABO matter?
  11. Platelet dosing
  12. Single-donor platelets reduce the risk of septic platelet transfusion reactions.
  13. Severe cutaneous ulceration following treatment with thalidomide for GVHD
  14. Economic consequences of alterations in platelet transfusion dose: Analysis of a prospective, randomized, double-blind trial
  15. Early prediction of poor hematopoietic progenitor cell (HPC) mobilization
  16. Considerations in the selection of a platelet component: Apheresis versus whole blood-derived
  17. Clinical consequences of alterations in platelet transfusion dose: A prospective, randomized, double-blind trial
  18. Metabolic consequences in very low birth weight infants transfused with older AS-1-preserved erythrocytes
  19. Plateletpheresis in 90- to 110-pound donors using the CS-3000 blood cell separator
  20. Platelet transfusion: A review of key concepts

View All Publications